Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial
Condition(s) studied
Investigational drug(s) / intervention(s)
Corneal Collagen Crosslinking: Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
Study summary
The purpose of this study is to determine whether corneal collagen crosslinking is effective in the treatment of progressive keratoconus.
Eligibility
Primary outcome measure(s)
- Kmax — 12 months
Kmax is defined as the steepest radius of curvature of the anterior corneal surface. It is measured by Scheimpflug-topography (Pentacam, Oculus Inc.). An increase of less than 1 diopter (D) from baseline at 12 months is defined as non-progression.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Ophthalmology, Sahlgrenska University Hospital | Mölndal | Västra Götalandsregionen |
More Sahlgrenska University Hospital trials in Sweden
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT01604135 on ClinicalTrials.gov ↗ ← All trials in Sweden